Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Jan Kus"'
Autor:
Matthias Münchhalfen, Richard Görg, Michael Haberl, Jens Löber, Jakob Willenbrink, Laura Schwarzt, Charlotte Höltermann, Christian Ickes, Leonard Hammermann, Jan Kus, Björn Chapuy, Andrea Ballabio, Sybille D. Reichardt, Alexander Flügel, Niklas Engels, Jürgen Wienands
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract Ligation of the B cell antigen receptor (BCR) initiates humoral immunity. However, BCR signaling without appropriate co-stimulation commits B cells to death rather than to differentiation into immune effector cells. How BCR activation deplet
Externí odkaz:
https://doaj.org/article/d3d3f15046064c9eadb2e5e5e120d8db
Autor:
Jürgen Wienands, Matthias Münchhalfen, Richard Görg, Jens Löber, Jakob Willenbrink, Laura Schwarzt, Charlotte Höltermann, Björn Chapuy, Christian Ickes, Jan Kus, Niklas Engels
Ligation of the B cell antigen receptor (BCR) initiates humoral immunity. However, mere BCR signaling without subsequent co-stimulation by T cells commits B cells to death rather than to differentiation into immune effector cells. It remains mysterio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4935a12cda5fa6aafeae2398b6bddca
https://doi.org/10.21203/rs.3.rs-1975280/v1
https://doi.org/10.21203/rs.3.rs-1975280/v1
Autor:
Monika Franczuk, Witold Tomkowski, Agnieszka Skoczylas, Jarosław Kober, Monika Szturmowicz, Jan Kus, Małgorzata Sobiecka, Katarzyna Lewandowska
Publikováno v:
Pulmonary hypertension.
Autor:
Jasna Tekavec-Trkanjec, Simona Littnerová, Nesrin Mogulkoc, Veronika Müller, Marta Hájková, Dragana Jovanovic, Jan Kus, Abigel Kolonics-Farkas, Karel Hejduk, Martina Sterclova, Martina Vasakova
Publikováno v:
Drug Safety
Introduction Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatel
Autor:
M. Tomczak, K. Roszkowski-Sliz, Jan Kus, Rafał Krenke, Magdalena Martusewicz-Boros, Ewa Jassem, Małgorzata Sobiecka, Witold Tomkowski, Katarzyna Górska, Krzysztof Sładek, Adam J. Białas, Beata Zolnowska, Sebastian Majewski, Katarzyna Lewandowska, Alicja Siemińska, Paweł Gomółka, Aleksander Kania, Wojciech J. Piotrowski, Elżbieta Wiatr
Publikováno v:
Medical University of Lodz, Poland. PublicUM
Publikováno v:
Advances in Respiratory Medicine. 85:161-168
Inflammatory bowel diseases are systemic disorders that can manifest in any location. The problem of respiratory system involvement is very important form clinical point of view. In the article we try to systematize the current knowledge on this topi
Autor:
Katarzyna Lewandowska, Piotr Radwan-Rohrenschef, Agata Gladzka, Małgorzata Bartosiewicz, Jan Kus, Dorota Klatka, Małgorzata Sobiecka, Iwona Bestry, Izabela Siemion-Szczesniak, Stefan Wesołowski
Publikováno v:
Idiopathic interstitial pneumonias.
Autor:
Katarzyna Lewandowska, Jan Kus, Guenther Wanke, Beata Zolnowska, Martina Vasakova, Sebastian Majewski, Ingeborg Beunders, Tatiana Peros-Golubicic, Katarzyna Górska, Martina Sterclova, Shani Jimmy, Veronika Müller
Publikováno v:
Idiopathic interstitial pneumonias.
Autor:
Veronika Müller, Martina Sterclova, Marta Hájková, Martina Vasakova, Nesrin Mogulkoc, Jasna Tekavec-Trkanjec, Marketa Janotova, Dragana Jovanovic, Jan Kus, Michal Svoboda
Publikováno v:
Idiopathic interstitial pneumonias.
Idiopathic pulmonary fibrosis (IPF) is a rare, deadly lung disease. Diagnosis and treatment possibilities are dependent on countries’ health systems. Comparison between countries is difficult due to data heterogenity. Our aim was to analyze IPF pat
Autor:
Nesrin Mogulkoc, Dragana Jovanovic, Abigel Kolonics-Farkas, Marketa Janotova, Marta Hájková, Jan Kus, Michal Svoboda, Martina Vasakova, Veronika Müller, Mordechai R. Kramer, Martina Sterclova, Jasna Tekavec-Trkanjec
Publikováno v:
Idiopathic interstitial pneumonias.
EMPIRE is an international, multicentre registry of idiopathic pulmonary fibrosis (IPF) patients in Central and Eastern Europe. Two approved treatments are available, nintedanib and pirfenidone. Nintedanib may increase the risk of bleeding and patien